Literature DB >> 30323103

Interstitial lung disease and inflammatory myopathy in antisynthetase syndrome with PL-12 antibody.

Ameen Jubber1, Mudita Tripathi1, James Taylor1.   

Abstract

We report the case of an 80-year-old Caucasian man with PL-12 antibody positive antisynthetase syndrome. He presented with progressive dyspnoea and weight loss, later developing dysphagia, mild proximal muscle weakness and mild sicca symptoms. Investigations revealed interstitial lung disease, inflammatory myopathy and an immunology profile consistent with PL-12 antisynthetase syndrome. Prednisolone and cyclophosphamide resulted in a significant improvement of all his symptoms. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  connective tissue disease; muscle disease; musculoskeletal syndromes; sjogren’s syndrome

Mesh：

Substances：

Year:  2018        PMID： 30323103      PMCID： PMC6194426          DOI： 10.1136/bcr-2018-226119

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  24 in total

1.  A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.

Authors:  Iago Pinal-Fernandez; Maria Casal-Dominguez; Julio A Huapaya; Jemima Albayda; Julie J Paik; Cheilonda Johnson; Leann Silhan; Lisa Christopher-Stine; Andrew L Mammen; Sonye K Danoff
Journal:  Rheumatology (Oxford)       Date:  2017-06-01       Impact factor: 7.580

2.  Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase).

Authors:  I N Targoff; F C Arnett
Journal:  Am J Med       Date:  1990-03       Impact factor: 4.965

3.  Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings.

Authors:  Marie-Pierre Debray; Raphael Borie; Marie-Pierre Revel; Jean-Marc Naccache; Antoine Khalil; Cécile Toper; Dominique Israel-Biet; Candice Estellat; Pierre-Yves Brillet
Journal:  Eur J Radiol       Date:  2014-12-03       Impact factor: 3.528

4.  Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis.

Authors:  Lénaig Mescam-Mancini; Yves Allenbach; Baptiste Hervier; Hervé Devilliers; Kuberaka Mariampillay; Odile Dubourg; Thierry Maisonobe; Romain Gherardi; Paulette Mezin; Corinna Preusse; Werner Stenzel; Olivier Benveniste
Journal:  Brain       Date:  2015-07-21       Impact factor: 13.501

5.  [Anti-synthetase syndrome: anti-PL-7, anti-PL-12 and anti-EJ].

Authors:  Fernando Henrique Carlos de Souza; Marcela Gran Pina Cruellas; Mauricio Levy-Neto; Samuel Katsuyuki Shinjo
Journal:  Rev Bras Reumatol       Date:  2013-08

Review 6.  Prevalence and clinical significance of rare antinuclear antibody patterns.

Authors:  Pieter Vermeersch; Xavier Bossuyt
Journal:  Autoimmun Rev       Date:  2013-04-11       Impact factor: 9.754

7.  Outcome of anti-PL12 positive patients with antisynthetase syndrome.

Authors:  Isabelle Marie; Séverine Josse; Olivier Decaux; Stéphane Dominique; Cédric Landron; Pascal Roblot; Stéphane Jouneau; Olivier Vittecoq; Fabienne Jouen
Journal:  Presse Med       Date:  2013-02-18       Impact factor: 1.228

8.  Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome.

Authors:  I Marie; S Josse; P Y Hatron; S Dominique; E Hachulla; A Janvresse; P Cherin; L Mouthon; O Vittecoq; J-F Menard; F Jouen
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-05       Impact factor: 4.794

Review 9.  Review: immune-mediated necrotizing myopathies--a heterogeneous group of diseases with specific myopathological features.

Authors:  W Stenzel; H-H Goebel; E Aronica
Journal:  Neuropathol Appl Neurobiol       Date:  2012-12       Impact factor: 8.090

10.  Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma.

Authors:  João Pedro Ferreira; Isabel Almeida; António Marinho; Conceição Cerveira; Carlos Vasconcelos
Journal:  ISRN Rheumatol       Date:  2012-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.